Blackstone acquisition of AYUMI : Global investment firm Blackstone said that private equity funds managed by it will acquire Japanese specialty pharma company AYUMI Pharmaceutical from Unison Capital and M3 for an undisclosed price.
AYUMI Pharmaceutical, which was founded in 2015, is focused on rheumatoid arthritis (RA) and orthopedic therapeutic areas. The Japanese specialty pharma company was established through the merger of the anti-rheumatic drug business of Santen Pharmaceutical with the medical business of Showa Yakuhin Kako.
For Blackstone, the acquisition of AYUMI Pharmaceutical marks its first controlling private equity investment in Japan.
Commenting on Blackstone acquisition of AYUMI, Atsuhiko Sakamoto – Senior Managing Director and Head of Japan Private Equity at Blackstone said: “Under the leadership of its seasoned management team, AYUMI has established a robust foundation as a leading specialty pharmaceutical company in the field of rheumatism and orthopedics – with world-class medical and scientific capabilities.
“We look forward to working with the Company to leverage Blackstone’s global footprint and expertise in this sector to help AYUMI meet the growing need for its RA and orthopedic products, invest in new, cutting-edge treatments and products, and continue supporting the Company’s mission of improving patient health.”
Calonal, the lead analgesic product of AYUMI Pharmaceutical is the market leading prescription acetaminophen drug in Japan.
In the RA field as well, the specialty pharma company is a market leader, with a portfolio comprising first-in-line treatments through synthetic and biosimilar products, that are prescribed to patients in all stages of RA diagnoses.
Ouchi Hikaru, Representative Director, President and CEO of AYUMI, Commenting on Blackstone acquisition of AYUMI, said: “It is a great honor to announce our new partnership with Blackstone to further accelerate our growth.
“Although we have already established a strong platform of growth in partnership with Unison Capital, from orthopedic therapeutic areas to RA areas and further through the new introduction of biosimilar products, we will need more investment for future growth.
“We have great expectations for our new shareholder in order to further enhance our presence in the Japanese pharmaceutical industry and to continue providing drug treatments that contribute to patients and to society.”
Subject to regulatory approvals and customary closing conditions, Blackstone acquisition of AYUMI is expected to be wrapped up in Q2 2019.
For more pharma acquisition news, keep following PharmaNewsDaily.com.